Transgene SA TRGNF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 158.20K | 159.10K | 79.70K | 80.10K | -- |
| Total Other Revenue | 1.58M | 1.59M | 1.45M | 1.46M | 2.60M |
| Total Revenue | 1.74M | 1.75M | 1.53M | 1.54M | 2.60M |
| Cost of Revenue | 8.97M | 9.02M | 9.30M | 9.34M | 10.16M |
| Gross Profit | -7.23M | -7.27M | -7.77M | -7.81M | -7.56M |
| SG&A Expenses | 2.40M | 2.41M | 2.05M | 2.06M | 2.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 108.20K | 108.80K | 649.60K | 652.40K | -30.60K |
| Total Operating Expenses | 11.48M | 11.54M | 12.01M | 12.06M | 12.28M |
| Operating Income | -9.74M | -9.79M | -10.48M | -10.52M | -9.68M |
| Income Before Tax | -9.11M | -9.17M | -10.61M | -10.66M | -10.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.11M | -9.17M | -10.61M | -10.66M | -10.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.11M | -9.17M | -10.61M | -10.66M | -10.95M |
| EBIT | -9.74M | -9.79M | -10.48M | -10.52M | -9.68M |
| EBITDA | -9.34M | -9.40M | -10.08M | -10.13M | -9.30M |
| EPS Basic | -0.03 | -0.03 | -0.07 | -0.07 | -0.08 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.04 | -0.04 | -0.05 |
| EPS Diluted | -0.03 | -0.04 | -0.07 | -0.07 | -0.09 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.04 | -0.04 | -0.05 |
| Average Basic Shares Outstanding | 274.37M | 274.37M | 156.55M | 156.55M | 132.51M |
| Average Diluted Shares Outstanding | 274.37M | 274.37M | 156.55M | 156.55M | 132.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |